2013 Q3 Form 10-Q Financial Statement

#000110465913060226 Filed on August 06, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $980.0K $97.00K $2.009M
YoY Change -68.52% -95.17% 2.92%
Cost Of Revenue $0.00 $0.00 $1.870M
YoY Change -100.0% -100.0% -3.61%
Gross Profit $980.0K $100.0K $140.0K
YoY Change 790.91% -28.57% 1300.0%
Gross Profit Margin 100.0% 103.09% 6.97%
Selling, General & Admin $3.580M $3.410M $2.220M
YoY Change 26.06% 53.6% -0.89%
% of Gross Profit 365.31% 3410.0% 1585.71%
Research & Development $20.42M $15.09M $11.11M
YoY Change 73.48% 35.77% 55.03%
% of Gross Profit 2083.37% 15090.0% 7938.57%
Depreciation & Amortization $730.0K $730.0K $820.0K
YoY Change -5.19% -10.98% -22.64%
% of Gross Profit 74.49% 730.0% 585.71%
Operating Expenses $20.42M $15.09M $11.11M
YoY Change 73.48% 35.77% 55.03%
Operating Profit -$23.27M -$18.66M -$13.49M
YoY Change 57.75% 38.33% 36.5%
Interest Expense $13.00K $519.0K $411.0K
YoY Change -96.59% 26.28% -5.3%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$23.14M -$19.02M -$13.77M
YoY Change 53.96% 38.13% 34.47%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.14M -$19.02M -$13.77M
YoY Change 53.96% 38.13% 34.47%
Net Earnings / Revenue -2361.22% -19608.25% -685.42%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.285M -$3.529M -$3.513M
COMMON SHARES
Basic Shares Outstanding 80.99M shares 80.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.6M $155.0M $78.70M
YoY Change 75.98% 96.93% 10.53%
Cash & Equivalents $14.63M $25.90M $18.56M
Short-Term Investments $122.0M $129.1M $60.10M
Other Short-Term Assets $2.500M $1.400M $1.700M
YoY Change 108.33% -17.65% -10.53%
Inventory
Prepaid Expenses
Receivables $900.0K $0.00 $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $139.9M $156.4M $80.40M
YoY Change 77.57% 94.56% 9.69%
LONG-TERM ASSETS
Property, Plant & Equipment $8.814M $7.338M $8.000M
YoY Change 16.49% -8.28% -20.0%
Goodwill $8.965M $8.965M
YoY Change 0.0%
Intangibles $23.07M $23.33M
YoY Change -4.21%
Long-Term Investments
YoY Change
Other Assets $157.0K $174.0K $400.0K
YoY Change -61.61% -56.5% 0.0%
Total Long-Term Assets $41.01M $39.80M $41.73M
YoY Change -0.04% -4.62% -7.68%
TOTAL ASSETS
Total Short-Term Assets $139.9M $156.4M $80.40M
Total Long-Term Assets $41.01M $39.80M $41.73M
Total Assets $181.0M $196.2M $122.1M
YoY Change 51.0% 60.68% 3.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.982M $2.069M $400.0K
YoY Change 54.72% 417.25% -20.0%
Accrued Expenses $13.81M $9.904M $6.600M
YoY Change 69.27% 50.06% 50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $5.300M
YoY Change -100.0% -100.0% 6.0%
Total Short-Term Liabilities $16.80M $12.50M $12.58M
YoY Change 11.0% -0.6% 20.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $8.600M
YoY Change -100.0% -100.0% -14.85%
Other Long-Term Liabilities $7.415M $6.636M $6.400M
YoY Change 16.5% 3.69% 6.67%
Total Long-Term Liabilities $7.415M $6.636M $15.00M
YoY Change 16.5% -55.76% -6.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.80M $12.50M $12.58M
Total Long-Term Liabilities $7.415M $6.636M $15.00M
Total Liabilities $24.21M $19.14M $27.58M
YoY Change -16.0% -30.61% 4.08%
SHAREHOLDERS EQUITY
Retained Earnings -$323.6M -$300.5M
YoY Change 30.85%
Common Stock $477.7M $475.0M
YoY Change 42.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $156.7M $177.1M $94.55M
YoY Change
Total Liabilities & Shareholders Equity $181.0M $196.2M $122.1M
YoY Change 51.0% 60.68% 3.06%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$23.14M -$19.02M -$13.77M
YoY Change 53.96% 38.13% 34.47%
Depreciation, Depletion And Amortization $730.0K $730.0K $820.0K
YoY Change -5.19% -10.98% -22.64%
Cash From Operating Activities -$17.45M -$18.06M -$11.96M
YoY Change 59.36% 51.0% 27.64%
INVESTING ACTIVITIES
Capital Expenditures -$980.0K -$760.0K -$80.00K
YoY Change 1300.0% 850.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $6.540M -$21.82M $9.160M
YoY Change 7.92% -338.21% -135.59%
Cash From Investing Activities $5.560M -$22.58M $9.080M
YoY Change -7.18% -348.68% -135.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 630.0K -9.090M -1.300M
YoY Change -93.42% 599.23% -103.62%
NET CHANGE
Cash From Operating Activities -17.45M -18.06M -11.96M
Cash From Investing Activities 5.560M -22.58M 9.080M
Cash From Financing Activities 630.0K -9.090M -1.300M
Net Change In Cash -11.26M -49.73M -4.180M
YoY Change -343.72% 1089.71% -705.8%
FREE CASH FLOW
Cash From Operating Activities -$17.45M -$18.06M -$11.96M
Capital Expenditures -$980.0K -$760.0K -$80.00K
Free Cash Flow -$16.47M -$17.30M -$11.88M
YoY Change 51.38% 45.62% 27.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2745000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-197000 USD
CY2013Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
129083000 USD
CY2013Q2 us-gaap Investments And Cash
InvestmentsAndCash
155000000 USD
CY2013Q2 cldx Working Capital
WorkingCapital
143900000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">(1)&#160; Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Celldex&#8221;) in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2012, which are included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;8, 2013.&#160; In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company&#8217;s financial position and results of operations for the interim periods presented.&#160; The year-end consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December&#160;31, 2013.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">At June&#160;30, 2013, the Company had cash, cash equivalents and marketable securities of $155.0 million and working capital of $143.9&#160;million. The Company incurred a loss of $36.3&#160;million for the six months ended June&#160;30, 2013.&#160; Net cash used in operations for the six months ended June&#160;30, 2013 was $35.3&#160;million. The Company believes that the cash, cash equivalents and marketable securities at June&#160;30, 2013 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs.&#160; These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company&#8217;s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company&#8217;s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company&#8217;s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company&#8217;s economic potential from products under development.</font></p> </div>
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36348000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35258000 USD
CY2013Q2 us-gaap Liabilities
Liabilities
19139000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5017603 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4316897 shares
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2689000 USD
CY2013Q2 cldx Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-141000 USD
cldx Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-197000 USD
CY2013Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-141000 USD
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2548000 USD
CY2013Q2 cldx Fair Value Assets Amount Transfers Between Measurement Levels
FairValueAssetsAmountTransfersBetweenMeasurementLevels
0 USD
CY2013Q2 cldx Fair Value Liabilities Amount Transfers Between Measurement Levels
FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels
0 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
58909000 USD
CY2013Q2 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
129121000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
164000 USD
CY2013Q2 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
86000 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
8000 USD
CY2013Q2 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
124000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59065000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
8965000 USD
CY2013Q2 us-gaap Goodwill
Goodwill
8965000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3763000 USD
CY2013Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4270000 USD
CY2012Q4 cldx Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
27596000 USD
CY2013Q2 cldx Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
27596000 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23833000 USD
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23326000 USD
CY2012Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
434000 USD
CY2013Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
422000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4661000 USD
CY2013Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4661000 USD
CY2012Q4 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
1118000 USD
CY2013Q2 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
1630000 USD
CY2012Q4 us-gaap Loans Payable
LoansPayable
472000 USD
CY2013Q2 us-gaap Loans Payable
LoansPayable
443000 USD
CY2012Q4 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
39000 USD
CY2013Q2 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
10000 USD
CY2012Q4 us-gaap Other Liabilities
OtherLiabilities
6724000 USD
CY2013Q2 us-gaap Other Liabilities
OtherLiabilities
7166000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
388000 USD
CY2013Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
530000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6336000 USD
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6636000 USD
cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
100000 USD
cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
200000 USD
CY2013Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
800000 USD
CY2012Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
800000 USD
CY2011Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
600000 USD
CY2013Q1 cldx Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
800000 USD
CY2012Q1 cldx Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
700000 USD
CY2011Q1 cldx Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
500000 USD
cldx Period For Which Base Of Operations Must Be Maintained
PeriodForWhichBaseOfOperationsMustBeMaintained
P5Y
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18563000 USD
CY2012Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12075000 shares
cldx Common Stock Exercise Of Full Over Allotment Option To Purchase Additional Shares By Underwriter
CommonStockExerciseOfFullOverAllotmentOptionToPurchaseAdditionalSharesByUnderwriter
1575000 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
43400000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
13800000 shares
cldx Common Stock Exercise Of Full Over Allotment Option To Purchase Additional Shares By Underwriter
CommonStockExerciseOfFullOverAllotmentOptionToPurchaseAdditionalSharesByUnderwriter
1800000 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
97000000 USD
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
676000 USD
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
448000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1384000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1088000 USD
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q2 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
3 item
CY2013Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
33000
CY2013Q2 cldx Operating Leases Term Of Lease
OperatingLeasesTermOfLease
P5Y5M
CY2013Q2 cldx Operating Leases Commencement Period Of Rental Obligations
OperatingLeasesCommencementPeriodOfRentalObligations
P5M
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
400000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
500000 USD
CY2013Q2 cldx Operating Leases Number Of Renewal Options
OperatingLeasesNumberOfRenewalOptions
2 item
CY2013Q2 cldx Operating Leases Period Of Renewal Options
OperatingLeasesPeriodOfRenewalOptions
P5Y
dei Entity Registrant Name
EntityRegistrantName
Celldex Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000744218
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
80987871 shares
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24897000 USD
CY2012Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
44000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1108000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7205000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
424000 USD
CY2012Q4 us-gaap Assets
Assets
125541000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
156430000 USD
CY2013Q2 us-gaap Assets
Assets
196233000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
745000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10960000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
5592000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17685000 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12503000 USD
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64359513 shares
CY2012Q4 us-gaap Liabilities
Liabilities
29767000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
64000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
357094000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264129000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
95774000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125541000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196233000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
177094000 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
5746000 USD
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80977696 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80977696 shares
CY2012Q2 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
40000 USD
CY2012Q2 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
96000 USD
CY2012Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1873000 USD
CY2012Q2 us-gaap Revenues
Revenues
2009000 USD
cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
75000 USD
cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
149000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
4218000 USD
us-gaap Revenues
Revenues
4442000 USD
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64359513 shares
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11114000 USD
CY2012Q2 us-gaap Royalty Expense
RoyaltyExpense
1873000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2219000 USD
CY2012Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
291000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
15497000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21881000 USD
us-gaap Royalty Expense
RoyaltyExpense
4218000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4536000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
583000 USD
us-gaap Costs And Expenses
CostsAndExpenses
31218000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13488000 USD
CY2012Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
126000 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
411000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13773000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-26776000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
331000 USD
us-gaap Interest Expense
InterestExpense
844000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27289000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25900000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-69159000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51957000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2294000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
-1323000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18430000 USD
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13813000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000 USD
CY2013Q2 us-gaap Revenues
Revenues
97000 USD
us-gaap Revenues
Revenues
2511000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
18755000 USD
us-gaap Costs And Expenses
CostsAndExpenses
38570000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18658000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-36059000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19016000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19157000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36545000 USD
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58733000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54439000 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1073000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
157000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
6000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
12000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1088000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
111000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-109000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
493000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
99000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-993000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
573000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25512000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20919000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11899000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39383000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
156000 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
29000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
50605000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
6664000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
1003000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
105423000 USD
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q2 cldx Available For Sale Securities Considered To Be Other Than Temporarily Impaired
AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
114187000 USD
CY2013Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
12000 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1435000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7338000 USD
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
174000 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2069000 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9904000 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
81000 USD
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
474942000 USD
CY2013Q2 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
47000 USD
cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
77000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-3000 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-300477000 USD
CY2013Q2 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
50000 USD
cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
100000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
2334000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15090000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29180000 USD
us-gaap Royalty Expense
RoyaltyExpense
2334000 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3411000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
507000 USD
CY2013Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
161000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
540000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
519000 USD
us-gaap Interest Expense
InterestExpense
829000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80899000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77482000 shares
CY2013Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-140000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-194000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
943000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1949000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
21000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1384000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
97000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-32000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
424000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-250000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
109000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
162000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20582000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
88845000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
917000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
21000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
-11029000 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
29000 USD
CY2013Q2 cldx Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0 USD

Files In Submission

Name View Source Status
0001104659-13-060226-index-headers.html Edgar Link pending
0001104659-13-060226-index.html Edgar Link pending
0001104659-13-060226.txt Edgar Link pending
0001104659-13-060226-xbrl.zip Edgar Link pending
a13-13533_110q.htm Edgar Link pending
a13-13533_1ex10d3.htm Edgar Link pending
a13-13533_1ex31d1.htm Edgar Link pending
a13-13533_1ex31d2.htm Edgar Link pending
a13-13533_1ex32d1.htm Edgar Link pending
cldx-20130630.xml Edgar Link completed
cldx-20130630.xsd Edgar Link pending
cldx-20130630_cal.xml Edgar Link unprocessable
cldx-20130630_def.xml Edgar Link unprocessable
cldx-20130630_lab.xml Edgar Link unprocessable
cldx-20130630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending